2025-521838-29-00RecruitingPhase 1
Study of IADADEMSTAT for the Treatment of Sickle Cell Disease.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 17 Jul 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 39 (estimated)
- First submitted
- 15 May 2025
- Start date
- 16 Oct 2025
- Lead sponsor
- Oryzon Genomics S.A.
- Diseases
- Sickle cell disease
- EU CT number
- 2025-521838-29-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 39
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (7)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Catala d'Oncologia | Badalona | Spain | Recruiting |
| Hospital Clinic Barcelona | Barcelona | Spain | Recruiting |
| Hospital de la Santa Creu i Sant Pau | Barcelona | Spain | Recruiting |
| Hospital Universitari Vall d'Hebron | Barcelona | Spain | Recruiting |
| Hospital Universitario La Paz | Madrid | Spain | Recruiting |
| Hospital General Universitario Gregorio Marañón | Madrid | Spain | Recruiting |
| University Hospital Virgen Del Rocio S.L. | Sevilla | Spain | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.